Denmeade S - Search Results

1

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT. Deek MP, et al. Among authors: denmeade s. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):948-956. doi: 10.1016/j.ijrobp.2019.08.008. Epub 2019 Aug 13. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419509 Free PMC article.

2

Prostate cancer: where are we and where are we going?

Denmeade SR, Isaacs JT. Denmeade SR, et al. Br J Urol. 1997 Mar;79 Suppl 1:2-7. doi: 10.1111/j.1464-410x.1997.tb00794.x. Br J Urol. 1997. PMID: 9088266 Review. No abstract available.

3

Complete androgen blockade for prostate cancer: what went wrong?

Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Laufer M, et al. Among authors: denmeade sr. J Urol. 2000 Jul;164(1):3-9. J Urol. 2000. PMID: 10840412 Free article. Review.

4

Development of prostate cancer treatment: the good news.

Denmeade SR, Isaacs JT. Denmeade SR, et al. Prostate. 2004 Feb 15;58(3):211-24. doi: 10.1002/pros.10360. Prostate. 2004. PMID: 14743459 Review.

5

Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.

Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O'Meally R, DeWeese TL, Denmeade SR. Lapidus RG, et al. Prostate. 2004 Feb 15;58(3):291-8. doi: 10.1002/pros.10331. Prostate. 2004. PMID: 14743469

6

A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.

Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. Sunkara U, et al. Among authors: denmeade s. J Interferon Cytokine Res. 2004 Jan;24(1):37-41. doi: 10.1089/107999004772719891. J Interferon Cytokine Res. 2004. PMID: 14980083 Clinical Trial.

7

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Sinibaldi VJ, et al. Am J Clin Oncol. 2006 Aug;29(4):395-8. doi: 10.1097/01.coc.0000225411.95479.b4. Am J Clin Oncol. 2006. PMID: 16891869 Clinical Trial.

8

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.

Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Bajaj GK, et al. Urology. 2007 Mar;69(3):526-31. doi: 10.1016/j.urology.2006.12.006. Urology. 2007. PMID: 17382158 Clinical Trial.

9

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Collins C, et al. Among authors: denmeade sr. Cancer Biol Ther. 2007 Sep;6(9):1360-7. doi: 10.4161/cbt.6.9.4541. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17786033 Free PMC article.

10

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.

Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. Kachhap SK, et al. Among authors: denmeade sr. PLoS One. 2007 Sep 5;2(9):e844. doi: 10.1371/journal.pone.0000844. PLoS One. 2007. PMID: 17786215 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page